Capocasale E, De Vecchi E, Mazzoni M P, Dalla Valle R, Pellegrino C, Ferretti S, Sianesi M, Iaria M
Division of General Surgery and Organ Transplantation, Department of Surgery, Parma University Hospital, Parma, Italy.
Division of Urology, Department of Surgery, Parma University Hospital, Parma, Italy.
Transplant Proc. 2014 Dec;46(10):3455-8. doi: 10.1016/j.transproceed.2014.07.071.
Surgical site infections (SSIs) and early urinary tract infections (UTIs) are well recognized postoperative kidney transplant complications. These complications seldom lead to graft loss, although they may result in significant morbidity with prolonged hospitalization. Thus, perioperative antibiotic prophylaxis (PAP) has traditionally been used in this setting. Between April 1988 and December 2012, we identified 1000 kidney transplant recipients (33 from living donors) who underwent prophylaxis with ceftriaxone before the surgical procedure. A retrospective analysis was conducted to evaluate both the incidence rate and outcome of SSIs and UTIs. Recipients who developed SSIs were also assessed to identify risk factors and potential correlations with different immunosuppressive regimens. A total of 20 SSIs (2%) and 93 UTIs (9.3%) were observed. The most significant risk factor for SSIs was urine leak (15.38%; odds ratio [OR], 12.3; P < .0001) followed by sirolimus-based maintenance immunosuppression therapy (5%; OR, 2.97; P = .04) and induction therapy with either antithymocyte globulin or basiliximab (3.18%; OR, 3.45; P = .01). Sex was identified as the only risk factor for UTI (female vs male, 17.1% vs 4.6%; P < .0001). We believe universal ceftriaxone-based prophylaxis is useful for preventing SSIs and UTIs, considering its effectiveness and safety profile.
手术部位感染(SSIs)和早期尿路感染(UTIs)是公认可识别的肾移植术后并发症。这些并发症很少导致移植肾丢失,尽管它们可能会因住院时间延长而导致显著的发病率。因此,围手术期抗生素预防(PAP)传统上一直用于这种情况。在1988年4月至2012年12月期间,我们确定了1000名肾移植受者(33名来自活体供体),他们在手术前接受了头孢曲松预防治疗。进行了一项回顾性分析,以评估SSIs和UTIs的发病率及结果。还对发生SSIs的受者进行了评估,以确定危险因素以及与不同免疫抑制方案的潜在相关性。共观察到20例SSIs(2%)和93例UTIs(9.3%)。SSIs最显著的危险因素是尿漏(15.38%;比值比[OR],12.3;P <.0001),其次是基于西罗莫司的维持免疫抑制治疗(5%;OR,2.97;P =.04)以及用抗胸腺细胞球蛋白或巴利昔单抗进行诱导治疗(3.18%;OR,3.45;P =.01)。性别被确定为UTI的唯一危险因素(女性与男性,17.1%对4.6%;P <.0001)。考虑到基于头孢曲松的普遍预防的有效性和安全性,我们认为其对预防SSIs和UTIs是有用的。